Allan’s Newsletter

Allan’s Newsletter

Share this post

Allan’s Newsletter
Allan’s Newsletter
Medscape Presents Long-COVID as Unassailable with Generic Drugs

Medscape Presents Long-COVID as Unassailable with Generic Drugs

LONG COVID IS REALLY COVID-19 VAXX-INJURY - TREAT WITH "IVERMECTIN PLUS", NATTOKINASE, ETC

Allan MacRae's avatar
Allan MacRae
Dec 13, 2024
∙ Paid
3

Share this post

Allan’s Newsletter
Allan’s Newsletter
Medscape Presents Long-COVID as Unassailable with Generic Drugs
Share

Medscape Presents Long-COVID as Unassailable with Generic Drugs

Patient Led Research Organization Fails to Cite Applications of Ivermectin, Colchicine, Hydroxychloroquine, and McCullough Protocol Base Spike Detoxification

Peter A. McCullough, MD, MPH Dec 13, 2024

READ IN APP

By Peter A. McCullough, MD, MPH

Just as the public was misled during the acute phase of the SARS-CoV-2 outbreak with Medscape newsletters to doctors indicating no outpatient treatments were working, a similar dismal message hit the inboxes of America’s physicians in an article by Tinker Ready on long-COVID.

The article quotes patient advocate Charlie McCone who leads The Patient-Led Research Collaborative:

McCone is a patient representative to the National Institutes of Health’s RECOVER-TLC research program, which met this summer to launch a series of clinical trials. He said the organization is making progress, but results from the clinical trials aren’t expected until 2028 — a long time for patients with long COVID to wait.

He noted the upcoming trial of low-dose rapamycin, which researchers hope will address some of the immune or infection-related dysfunction that drives long COVID.

After McCone spent hours in bed for more than a year, he can now work at the computer for about 2 hours a day. His shortness of breath improved after he started taking Plavix.

“That's up from about 30 minutes. I can leave the house occasionally, once to twice a week, depending on the week,” he said.

McCone and others are calling for better continuing education for doctors about long COVID for doctors and more publicly available information to help patients know what drugs are already out there and might benefit them.

“Read the research, provide some low-risk treatment options to your patients, and let your patient decide,” he advised doctors. “I don't think this is asking you too much. This is a health crisis that's impacting every aspect of society.”

This post is for paid subscribers

Already a paid subscriber? Sign in
© 2025 Allan MacRae
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share